vs
Apollo Commercial Real Estate Finance, Inc.（ARI）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是Apollo Commercial Real Estate Finance, Inc.的1.0倍（$75.5M vs $73.3M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 4.0%），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs -4.6%）
阿波罗商业房地产金融公司是一家房地产投资信托企业，主要发起、收购并管理商业地产债务资产，包括优先抵押贷款、夹层贷款及商业抵押贷款支持证券，主营美国市场，致力于为投资者创造稳定收益。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
ARI vs PBYI — 直观对比
营收规模更大
PBYI
是对方的1.0倍
$73.3M
营收增速更快
PBYI
高出23.7%
4.0%
两年增速更快
PBYI
近两年复合增速
-4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $73.3M | $75.5M |
| 净利润 | $29.2M | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | 39.7% | 22.7% |
| 净利率 | 39.9% | — |
| 营收同比 | 4.0% | 27.7% |
| 净利润同比 | -28.2% | — |
| 每股收益（稀释后） | $0.19 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARIPBYI
| Q4 25 | $73.3M | $75.5M | ||
| Q3 25 | $61.6M | $54.5M | ||
| Q2 25 | $70.9M | $52.4M | ||
| Q1 25 | $65.8M | $46.0M | ||
| Q4 24 | $70.5M | $59.1M | ||
| Q3 24 | $71.6M | $80.5M | ||
| Q2 24 | $81.1M | $47.1M | ||
| Q1 24 | $80.5M | $43.8M |
净利润ARIPBYI
| Q4 25 | $29.2M | — | ||
| Q3 25 | $50.8M | $8.8M | ||
| Q2 25 | $20.7M | $5.9M | ||
| Q1 25 | $26.0M | $3.0M | ||
| Q4 24 | $40.7M | — | ||
| Q3 24 | $-91.5M | $20.3M | ||
| Q2 24 | $35.8M | $-4.5M | ||
| Q1 24 | $-104.5M | $-4.8M |
毛利率ARIPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
营业利润率ARIPBYI
| Q4 25 | 39.7% | 22.7% | ||
| Q3 25 | 82.8% | 17.6% | ||
| Q2 25 | 29.4% | 12.7% | ||
| Q1 25 | 39.7% | 8.7% | ||
| Q4 24 | 57.9% | 22.6% | ||
| Q3 24 | -127.8% | 27.4% | ||
| Q2 24 | 44.2% | -4.6% | ||
| Q1 24 | -129.6% | -5.3% |
净利率ARIPBYI
| Q4 25 | 39.9% | — | ||
| Q3 25 | 82.4% | 16.2% | ||
| Q2 25 | 29.3% | 11.2% | ||
| Q1 25 | 39.5% | 6.5% | ||
| Q4 24 | 57.7% | — | ||
| Q3 24 | -127.9% | 25.2% | ||
| Q2 24 | 44.1% | -9.6% | ||
| Q1 24 | -129.8% | -11.0% |
每股收益（稀释后）ARIPBYI
| Q4 25 | $0.19 | $0.26 | ||
| Q3 25 | $0.34 | $0.17 | ||
| Q2 25 | $0.12 | $0.12 | ||
| Q1 25 | $0.16 | $0.06 | ||
| Q4 24 | $0.25 | $0.40 | ||
| Q3 24 | $-0.69 | $0.41 | ||
| Q2 24 | $0.23 | $-0.09 | ||
| Q1 24 | $-0.76 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $139.8M | $97.5M |
| 总债务越低越好 | — | $22.7M |
| 股东权益账面价值 | $1.9B | $130.3M |
| 总资产 | $9.9B | $216.3M |
| 负债/权益比越低杠杆越低 | — | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资ARIPBYI
| Q4 25 | $139.8M | $97.5M | ||
| Q3 25 | $245.9M | $94.4M | ||
| Q2 25 | $177.6M | $96.0M | ||
| Q1 25 | $166.4M | $93.2M | ||
| Q4 24 | $317.4M | $101.0M | ||
| Q3 24 | $194.3M | $96.7M | ||
| Q2 24 | $174.7M | $96.8M | ||
| Q1 24 | $161.2M | $107.2M |
总债务ARIPBYI
| Q4 25 | — | $22.7M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $68.0M | ||
| Q3 24 | — | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益ARIPBYI
| Q4 25 | $1.9B | $130.3M | ||
| Q3 25 | $1.9B | $115.3M | ||
| Q2 25 | $1.8B | $104.7M | ||
| Q1 25 | $1.9B | $97.1M | ||
| Q4 24 | $1.9B | $92.1M | ||
| Q3 24 | $1.9B | $71.1M | ||
| Q2 24 | $2.0B | $48.5M | ||
| Q1 24 | $2.0B | $51.0M |
总资产ARIPBYI
| Q4 25 | $9.9B | $216.3M | ||
| Q3 25 | $9.5B | $202.9M | ||
| Q2 25 | $9.8B | $194.9M | ||
| Q1 25 | $8.8B | $196.2M | ||
| Q4 24 | $8.4B | $213.3M | ||
| Q3 24 | $9.1B | $220.7M | ||
| Q2 24 | $9.3B | $205.0M | ||
| Q1 24 | $9.2B | $214.1M |
负债/权益比ARIPBYI
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $142.5M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | — | $14.4M |
| 自由现金流率自由现金流/营收 | — | 19.1% |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | 4.88× | — |
| 过去12个月自由现金流最近4个季度 | — | $41.7M |
8季度趋势，按日历期对齐
经营现金流ARIPBYI
| Q4 25 | $142.5M | $14.4M | ||
| Q3 25 | $31.7M | $9.7M | ||
| Q2 25 | $63.2M | $14.1M | ||
| Q1 25 | $39.3M | $3.6M | ||
| Q4 24 | $200.3M | $15.6M | ||
| Q3 24 | $47.2M | $11.0M | ||
| Q2 24 | $50.2M | $1.0M | ||
| Q1 24 | $52.8M | $11.2M |
自由现金流ARIPBYI
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $9.7M | ||
| Q2 25 | — | $14.1M | ||
| Q1 25 | — | $3.6M | ||
| Q4 24 | — | $15.6M | ||
| Q3 24 | — | $11.0M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | — |
自由现金流率ARIPBYI
| Q4 25 | — | 19.1% | ||
| Q3 25 | — | 17.7% | ||
| Q2 25 | — | 26.8% | ||
| Q1 25 | — | 7.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | — |
资本支出强度ARIPBYI
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
现金转化率ARIPBYI
| Q4 25 | 4.88× | — | ||
| Q3 25 | 0.62× | 1.10× | ||
| Q2 25 | 3.05× | 2.41× | ||
| Q1 25 | 1.51× | 1.21× | ||
| Q4 24 | 4.93× | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | 1.40× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
